TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9339268
Drug: xanomeline (dose-dependent)
Normalized name: Xanomeline
DrugBank: Xanomeline (DB15357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: xanomeline (dose-dependent)
Study: 8471827
Drug: Fluvoxamine (200-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (200-300 mg/day)
Study: 8471827
Drug: Maprotiline (200-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (200-300 mg/day)
Study: 3535049
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pivampicillin and pivmecillinam
Study: 29975601
Drug: High quantity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High quantity of carbohydrate (CHO) at 1.5 g/kg body weight
Study: 29975601
Drug: Low quantity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low quantity of carbohydrate (CHO) at 0.8 g/kg body weight
Study: 26822146
Drug: bexarotene 300
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: bexarotene 300 mg
Study: 17962429
Drug: varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: varenicline 1 mg twice a day
Study: 11206672
Drug: CODAS‐Verapamil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CODAS‐Verapamil (200 mg)
Study: 11206672
Drug: CODAS‐Verapamil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CODAS‐Verapamil (300 mg)
Study: 11206672
Drug: CODAS‐Verapamil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CODAS‐Verapamil (400 mg)
Study: 11206672
Drug: CODAS‐Verapamil (bedtime
Approvals — FDA: no, EMA: no, PMDA: no
Description: CODAS‐Verapamil (bedtime dosing)
Study: 18237589
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose <81 mg/dl (hypoglycemia)
Study: 18237589
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose >199 mg/dl (severe hyperglycemia)
Study: 18237589
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose 81 to 99 mg/dl (euglycemic group)
Study: 18237589
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose 81 to 99 mg/dl
Study: 18237589
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose >199 mg/dl
Study: 18237589
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose 150 to 199 mg/dl
Study: 11863094
Drug: Original CISCA/VB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original CISCA/VB regimen (100% dose)
Study: 11863094
Drug: Low-dose CISCA/VB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose CISCA/VB regimen (80% dose)
Study: 10469180
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A (single viral inactivated concentrate) - 32.5 IU kg-1
Study: 10469180
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B (double viral inactivated concentrate) - 27 IU kg-1
Study: 7554704
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg for 1 day and 250 mg for 4 subsequent days
Study: 7554704
Drug: Terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60 mg twice daily for 12 days
Study: 2177216
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 400 micrograms day‐1
Study: 2177216
Drug: Inhaled nedocromil
Normalized name: nedocromil Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nedocromil sodium (NDS) 16 mg day‐1
Study: 6986893
Drug: Bromocriptine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (after stopping therapy)
Study: 23375753
Drug: Plant sterol-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol-enriched margarine (3.0 g/d of plant sterols)
Study: 23375753
Drug: Plant stanol-enriched
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol-enriched margarine (3.0 g/d of plant stanols)
Study: 16969707
Drug: Rebeccamycin analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebeccamycin analog 500 mg/m2 IV bolus every 21 days (arm 1)
Study: 16969707
Drug: Rebeccamycin analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebeccamycin analog 140 mg/m2 IV bolus daily x 5 days, every 21 days (arm 2)
Study: 9261762
Drug: Theophylline with
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline with prednisone infusion
Study: 9261762
Drug: Prednisone infusion
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone infusion alone
Study: 25847553
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation group (TFG) - received two 500mg capsules of test formulation daily for 3 months
Study: 21558566
Drug: High-calorie-expenditure (HCE)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calorie-expenditure (HCE) exercise (3,000-3,500 kcal/wk daily walking)
Study: 20877184
Drug: Systemic hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic hypothermia (n = 46), induced within 10 hours after birth, decreasing rectal temperature to 33.5°C for 72 hours
Study: 20877184
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (n = 47)
Study: 15342617
Drug: Frovatriptan 2.5
Normalized name: frovatriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan 2.5 mg oral dose
Study: 9088589
Drug: GR117289C 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR117289C 10 mg
Study: 9088589
Drug: GR117289C 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR117289C 100 mg
Study: 9088589
Drug: GR117289C 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR117289C 300 mg
Study: 8227803
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release nifedipine therapy
Study: 3100446
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg BW carnitine daily as a continuous infusion over 16 h
Study: 3100446
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg BW carnitine daily
Study: 3259521
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol (average daily dose 160 mg)
Study: 31805052
Drug: Intralesional meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional meglumine antimoniate therapy (IL‐MA)
Study: 31805052
Drug: Endovenous meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endovenous meglumine antimoniate therapy (EV‐MA)
Study: 25863828
Drug: 6-times-weekly home
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-times-weekly home nocturnal hemodialysis
Study: 25863828
Drug: 3-times-weekly hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-times-weekly hemodialysis (conventional arm)
Study: 25863828
Drug: 6-month running
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month running treatment data analysis
Study: 19429874
Drug: CIPII (Continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIPII (Continuous Intraperitoneal Insulin Infusion)
Study: 3803413
Drug: Pinacidil (62
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil (62 +/- 18 mg/day)
Study: 3803413
Drug: Hydralazine (128
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (128 +/- 28 mg/day)
Study: 28514309
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTA) 200 U subcutaneous injection, once daily at the painful area
Study: 17519319
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml water
Study: 17469765
Drug: 330 ml
Normalized name: ALCOHOL 247.5 mL in 330 mL EXTRACORPOREAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 330 ml beer per day for 30 consecutive days (EG)
Study: 15206999
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not taking amiodarone or QT-prolonging drugs)
Study: 12228873
Drug: Hormonal treatments
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatments
Study: 9707042
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with ranitidine bismuth citrate (RBC) 400 mg b.i.d., clarithromycin 500 mg b.i.d., and metronidazole 500 mg b.i.d.
Study: 9707042
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with ranitidine bismuth citrate (RBC) 400 mg b.i.d. and clarithromycin 500 mg b.i.d.
Study: 9707042
Drug: Both triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both triple and dual therapy
Study: 7793859
Drug: Atevirdine mesylate
Normalized name: mesylate
DrugBank: Atevirdine (DB12264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atevirdine mesylate (400 mg)
Study: 7793859
Drug: Atevirdine mesylate
Normalized name: mesylate
DrugBank: Atevirdine (DB12264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atevirdine mesylate (800 mg)
Study: 7793859
Drug: Atevirdine mesylate
Normalized name: mesylate
DrugBank: Atevirdine (DB12264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atevirdine mesylate (1,200 mg)
Study: 7793859
Drug: Atevirdine mesylate
Normalized name: mesylate
DrugBank: Atevirdine (DB12264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atevirdine mesylate (1,600 mg)
Study: 7793859
Drug: Atevirdine mesylate
Normalized name: mesylate
DrugBank: Atevirdine (DB12264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atevirdine mesylate (all doses)
Study: 2307239
Drug: FAM chemotherapy
Normalized name: fam-trastuzumab deruxtecan-nxki Injection [Enhertu]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAM chemotherapy plus aminoglutethimide/hydrocortisone (AG/HC) (250 mg bid AG + 20 mg bid HC)
Study: 26932146
Drug: DMF 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMF 240 mg BID
Study: 27207449
Drug: DMF 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMF 240 mg TID
Study: 24345717
Drug: Venlafaxine extended
Normalized name: Desvenlafaxine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine extended release (ER) (75-300 mg/d)
Study: 21537042
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg subcutaneously every 4 weeks until the end of the last cycle)
Study: 21537042
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (anthracycline/cyclophosphamide with or without taxane)
Study: 14756851
Drug: Diclofenac softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac softgel 100 mg
Study: 14756851
Drug: Diclofenac softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac softgel 100 mg plus caffeine 100 mg
Study: 10030097
Drug: Classical pharmacological
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical pharmacological treatments (diuretics and beta blockers)
Study: 10030097
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs (calcium antagonists and angiotensin converting enzyme inhibitors)
Study: 10030097
Drug: Non pharmacological
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non pharmacological therapies (sodium restriction, weight reduction, avoidance of alcohol intake, calcium and potassium supplementation)
Study: 8047525
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine system 7 mg per day
Study: 8047525
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine system 14 mg per day
Study: 8047525
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine system 21 mg per day
Study: 31311361
Drug: Control medication
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control medication at baseline
Study: 11057350
Drug: Emedastine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emedastine 0.05% ophthalmic solution BID
Study: 11057350
Drug: Levocabastine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine 0.05% ophthalmic suspension BID
Study: 31784483
Drug: Drug effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug effect of -0.5 points in MDS-UPDRS per year
Study: 27622699
Drug: Fluticasone Furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone Furoate (FF) 25 µg once daily
Study: 27622699
Drug: Fluticasone Furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone Furoate (FF) 50 µg once daily
Study: 27622699
Drug: Fluticasone Furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone Furoate (FF) 100 µg once daily
Study: 27622699
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate (FP) 100 µg twice daily
Study: 23739219
Drug: Misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 400 µg vaginally 4 hours prior to IUD insertion
Study: 14660300
Drug: Epoetin-alpha (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-alpha (150 U/kg or 250 U/kg, thrice weekly for 12 weeks)
Study: 25519197
Drug: High-dose probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose probiotics (10^10 cells for 21 days)
Study: 25519197
Drug: Standard-dose probiotics
Normalized name: PROBIOTIC
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose probiotics (10^10 cells for 14 days)
Study: 25519197
Drug: Lower-dose probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose probiotics (10^9 cells for 21 days)
Study: 24378016
Drug: 4g/day prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g/day prescription omega‐3 fatty acid ethyl ester (P‐OM3)
Study: 24378016
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (P‐OM3 + ERN)
Study: 10711900
Drug: Topical aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aqueous suppressants
Study: 10711900
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no topical aqueous suppressants)
Study: 7661062
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg loading dose
Study: 7661062
Drug: Aspirin 500
Normalized name: aspirin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 500 mg loading dose
Study: 7661062
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg loading dose
Study: 7661062
Drug: Aspirin 40/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 40/40 mg combination
Study: 7661062
Drug: Different combinations
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different combinations of aspirin doses
Study: 2194770
Drug: Midazolam (0.1-0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1-0.15 mg/kg)
Study: 2194770
Drug: Diazepam (0.2-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.2-0.4 mg/kg)
Study: 498700
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil
Study: 31793991
Drug: Presatovir 200
Normalized name: Presatovir
DrugBank: Presatovir (DB12165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presatovir 200 mg
Study: 31793991
Drug: Presatovir 200
Normalized name: Presatovir
DrugBank: Presatovir (DB12165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presatovir 200 mg (in lymphopenic patients)
Study: 23993706
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (0.5 mg/kg BW daily) for 2 weeks
Study: 22290033
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (fluoxetine)
Study: 22290033
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and fluoxetine (CBT+fluoxetine)
Study: 15311169
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of beta-blockers
Study: 11323149
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg codeine
Study: 8225629
Drug: 1% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin hydrochloride gel
Study: 2952095
Drug: Amantadine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (300 mg/day, t.i.d.)
Study: 28095573
Drug: SB204 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB204 2% twice daily
Study: 28095573
Drug: SB204 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB204 4% once daily
Study: 28095573
Drug: SB204 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB204 4% twice daily
Study: 17846933
Drug: Movina (St
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movina (St John's Wort product, 300 mg Hypericum perforatum, two tablets daily)
Study: 17846933
Drug: Control (commercially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (commercially available multivitamin tablet, Vitamineral)
Study: 15151614
Drug: LAT (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAT (lansoprazole 30 mg b.d., amoxycillin 1000 mg b.d., tinidazole 500 mg b.d.)
Study: 15151614
Drug: LAC (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC (lansoprazole 30 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Study: 9841945
Drug: Cotton pledge
Normalized name: Cotton
DrugBank: Cotton (DB10707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotton pledge soaked in 5% cocaine solution (middle nasal meatus stimulation)
Study: 7986255
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg cyclandelate
Study: 31942818
Drug: Hand-Arm Bimanual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand-Arm Bimanual Intensive Therapy (HABIT)
Study: 27611301
Drug: rTMS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS treatment (10 sessions over the bilateral dorsolateral prefrontal cortex)
Study: 26463489
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg qd)
Study: 9404904
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg qd)
Study: 9794155
Drug: Mono‐Tildiem LP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mono‐Tildiem LP 300 (300 mg)
Study: 9794155
Drug: Adizem XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adizem XL (300 mg)
Study: 9794155
Drug: Cardizem (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardizem (300 mg)
Study: 9794155
Drug: Dilacor (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilacor (240 mg)
Study: 8605713
Drug: 14 gauge
Normalized name: intravenous catheter 14 gauge X 2" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 gauge needles at QB 500 cc/min
Study: 8605713
Drug: 17 gauge
Normalized name: lancets 17 gauge MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 gauge needles at QB 500 cc/min
Study: 8605713
Drug: 14 gauge
Normalized name: intravenous catheter 14 gauge X 2" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 gauge needles at QB 200 cc/min
Study: 8605713
Drug: 17 gauge
Normalized name: lancets 17 gauge MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 gauge needles at QB 200 cc/min
Study: 31583805
Drug: Responsive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responsive treatment
Study: 20495139
Drug: Phenylephrine 100
Normalized name: phenylephrine 100 mcg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 100 μg/min
Study: 28235526
Drug: Ephedrine 5
Normalized name: pseudoephedrine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 5 mg/min
Study: 26032587
Drug: Dihydromyricetin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydromyricetin (150 mg, two capsules twice daily for three months)
Study: 26032587
Drug: Placebo (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (150 mg, two capsules twice daily for three months)
Study: 21462332
Drug: Isolated coumarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated coumarin in a capsule (reference)
Study: 21462332
Drug: Cinnamon in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon in capsules
Study: 18707693
Drug: Duloxetine (switch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (switch method: direct switch or start-taper switch)
Study: 18707693
Drug: Duloxetine (start-taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (start-taper switch)
Study: 18707693
Drug: Duloxetine (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (overall treatment)
Study: 15147430
Drug: SRL‐ST (sirolimus-steroid)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL‐ST (sirolimus-steroid)
Study: 28784701
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (LGG) supplementation (10 billion CFU and 225 mg of inulin)